EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Unlocking the potential of GLP-1 receptor agonists in ocular therapeutics: from molecular pathways to clinical impact

Zhixuan Xie, Zuyi Yang, Dianzhe Tian, Youxin Chen

Frontiers in Pharmacology · 24.07.2025 · 16

DOI: 10.3389/fphar.2025.1618079 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 24.07.2025. Verfasst von Zhixuan Xie und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for diabetes and obesity, exhibit pleiotropic effects—including anti-inflammatory, antioxidant, and neuroprotective properties—that position them as transformative candidates for ocular therapeutics. Ocular diseases such as glaucoma and diabetic retinopathy (DR) are driven by multifactorial pathogenesis. Current therapies often target specific pathways or symptoms, and the potential effect of GLP-1RAs on the eye is still debated. The latest research and trials on the effect of GLP-1RAs in the eye were searched until April 2025, including thorough cellular studies, animal studies, and clinical observation surrounding glaucoma, diabetic retinopathy, and other ocular diseases. This review delineates the multifaceted mechanisms by which GLP-1RAs exert ocular benefits, including retinal ganglion cell (RGC) rescue via calcium channel and GABAergic modulation, mitochondrial protection through PINK1/Parkin-mediated mitophagy and ERK1/2-HDAC6 signaling, as well as potent anti-inflammatory effects via cytokine reduction and immune cell recruitment inhibition. Moreover, GLP-1RAs contribute to retinal remodeling by stabilizing vascular integrity and extracellular matrix homeostasis, and they display anti-angiogenic properties critical for mitigating neovascular complications. Clinical evidence underscores a reduced incidence of glaucoma and potential benefits in diabetic retinopathy. However, conflicting evidence highlights context-dependent risks, such as early DR worsening in poorly controlled glycemic states. In conclusion, this review synthesizes molecular insights and clinical evidence to underscore GLP-1RAs’ potential as multi-targeted disease-modifying agents, urging further research to translate preclinical promise into safe, effective ocular therapies.

Schlagwörter

Stichwörter der Autor:innen

diabetic retinopathyglaucomaglucagon-like peptide-1 receptor agonistsmechanismocular diseases

Autor:innen und Institutionen

  • Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
  • Key Lab of Ocular Fundus Diseases, Chinese Academy of Medical Sciences, Beijing, China.
  • Eight-Year Medical Doctor Program, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Zitieren

APA

Xie, Z., Yang, Z., Tian, D., & Chen, Y. (2025). Unlocking the potential of GLP-1 receptor agonists in ocular therapeutics: from molecular pathways to clinical impact. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1618079

Vancouver

Xie Z, Yang Z, Tian D, Chen Y. Unlocking the potential of GLP-1 receptor agonists in ocular therapeutics: from molecular pathways to clinical impact. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1618079

BibTeX
@article{Xie2025,
  author = {Xie, Zhixuan and Yang, Zuyi and Tian, Dianzhe and Chen, Youxin},
  title = {Unlocking the potential of GLP-1 receptor agonists in ocular therapeutics: from molecular pathways to clinical impact},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1618079}
}
Kostenlos starten →